Sinus Excision/Destruction, Implants, and Repair 7.01.99
Summary
Excellus BlueCross BlueShield policy 7.01.99, Sinus Excision/Destruction, Implants, and Repair, has a current effective date of December 18, 2025. The December 18, 2025 annual review added medically necessary criteria for the SINUVA implant: members must be 18 or older, have recurrent nasal polyps secondary to chronic rhinosinusitis, have a history of ethmoid sinus surgery and be candidates for revision sinus surgery, have nasal obstruction or congestion despite intranasal steroid irrigations or sprays, and have had previous treatment, contraindication or intolerance to conventional nasal polyp therapy. The policy continues to consider the PROPEL drug-eluting sinus stent, repeat use of drug-eluting sinus stents, absorbable nasal implants (e.g., Latera) for nasal valve collapse, radiofrequency ablation of the nasal valve (e.g., VivAer stylus) and posterior nasal nerve excision or destruction by cryoablation, RF ablation or laser ablation investigational.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.